NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"). Investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether Northwest Biotherapeutics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 19, 2014, a report published by the website TheStreet.com states that, "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct." MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics.
On this news, shares of Northwest Biotherapeutics fell $0.87 per share to $8.04, or more than 10.37%, in intraday trading on June 19, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT: Robert S. Willoughby Pomerantz LLP firstname.lastname@example.orgSource:Pomerantz LLP